These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 31203233

  • 1. Serum apolipoproteins and apolipoprotein-defined lipoprotein subclasses: a hypothesis-generating prospective study of cardiovascular events in T1D.
    Basu A, Bebu I, Jenkins AJ, Stoner JA, Zhang Y, Klein RL, Lopes-Virella MF, Garvey WT, Budoff MJ, Alaupovic P, Lyons TJ, Diabetes Control Complications Trial/Epidemiology of Diabetes Interventions Complications Research Group.
    J Lipid Res; 2019 Aug; 60(8):1432-1439. PubMed ID: 31203233
    [Abstract] [Full Text] [Related]

  • 2. Associations among apolipoproteins, oxidized high-density lipoprotein and cardiovascular events in patients on hemodialysis.
    Honda H, Hirano T, Ueda M, Kojima S, Mashiba S, Hayase Y, Michihata T, Shishido K, Takahashi K, Hosaka N, Ikeda M, Sanada D, Shibata T.
    PLoS One; 2017 Aug; 12(5):e0177980. PubMed ID: 28542510
    [Abstract] [Full Text] [Related]

  • 3. Apolipoprotein-defined lipoprotein subclasses, serum apolipoproteins, and carotid intima-media thickness in T1D.
    Basu A, Jenkins AJ, Stoner JA, Zhang Y, Klein RL, Lopes-Virella MF, Garvey WT, Schade DS, Wood J, Alaupovic P, Lyons TJ, Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.
    J Lipid Res; 2018 May; 59(5):872-883. PubMed ID: 29576550
    [Abstract] [Full Text] [Related]

  • 4. Association of apolipoprotein C3 with insulin resistance and coronary artery calcium in patients with type 1 diabetes.
    Buckner T, Shao B, Eckel RH, Heinecke JW, Bornfeldt KE, Snell-Bergeon J.
    J Clin Lipidol; 2021 May; 15(1):235-242. PubMed ID: 33257283
    [Abstract] [Full Text] [Related]

  • 5. Apolipoprotein-defined lipoproteins and apolipoproteins: associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort.
    Jenkins AJ, Yu J, Alaupovic P, Basu A, Klein RL, Lopes-Virella M, Baker NL, Hunt KJ, Lackland DT, Garvey WT, Lyons TJ, DCCT/EDIC Research Group.
    J Diabetes Complications; 2013 May; 27(5):447-53. PubMed ID: 23850262
    [Abstract] [Full Text] [Related]

  • 6. A prospective study of the APOA1 XmnI and APOC3 SstI polymorphisms in the APOA1/C3/A4 gene cluster and risk of incident myocardial infarction in men.
    Liu S, Song Y, Hu FB, Niu T, Ma J, Gaziano M, Stampfer MJ.
    Atherosclerosis; 2004 Nov; 177(1):119-26. PubMed ID: 15488874
    [Abstract] [Full Text] [Related]

  • 7. Associations between Alcohol Consumption and HDL Subspecies Defined by ApoC3, ApoE and ApoJ: the Cardiovascular Health Study.
    Wilkens TL, Sørensen H, Jensen MK, Furtado JD, Dragsted LO, Mukamal KJ.
    Curr Probl Cardiol; 2023 Jan; 48(1):101395. PubMed ID: 36096454
    [Abstract] [Full Text] [Related]

  • 8. Association of apolipoproteins C3 and E with metabolic changes in HIV-infected adults treated with a protease-inhibitor-containing antiretroviral therapy.
    Bard JM, Lassalle R, Capeau J, Bach-Ngohou K, Nazih-Sanderson F, Rémy G, Reynes J, Ecobichon JL, Savès M, Raffi F, Aproco-Copilote Study Group.
    Antivir Ther; 2006 Jan; 11(3):361-70. PubMed ID: 16759053
    [Abstract] [Full Text] [Related]

  • 9. Blood lipids and lipoproteins in relation to incidence and mortality risks for CVD and cancer in the prospective EPIC-Heidelberg cohort.
    Katzke VA, Sookthai D, Johnson T, Kühn T, Kaaks R.
    BMC Med; 2017 Dec 19; 15(1):218. PubMed ID: 29254484
    [Abstract] [Full Text] [Related]

  • 10. Serum Levels of Apolipoproteins and Incident Type 2 Diabetes: A Prospective Cohort Study.
    Brahimaj A, Ligthart S, Ikram MA, Hofman A, Franco OH, Sijbrands EJ, Kavousi M, Dehghan A.
    Diabetes Care; 2017 Mar 19; 40(3):346-351. PubMed ID: 28031419
    [Abstract] [Full Text] [Related]

  • 11. The apoB/apoA1 ratio predicts future cardiovascular events in patients with rheumatoid arthritis.
    Öhman M, Öhman ML, Wållberg-Jonsson S.
    Scand J Rheumatol; 2014 Mar 19; 43(4):259-64. PubMed ID: 24689997
    [Abstract] [Full Text] [Related]

  • 12. Genetic Risk Factors for CVD in Type 1 Diabetes: The DCCT/EDIC Study.
    Bebu I, Keshavarzi S, Gao X, Braffett BH, Canty AJ, Herman WH, Orchard TJ, Dagogo-Jack S, Nathan DM, Lachin JM, Paterson AD, DCCT/EDIC Research Group.
    Diabetes Care; 2021 Jun 19; 44(6):1309-1316. PubMed ID: 33883194
    [Abstract] [Full Text] [Related]

  • 13. Serum Apolipoprotein-A2 Levels Are a Strong Predictor of Future Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention.
    Akiyama T, Ikegami R, Kubota N, Takano T, Yoneyama S, Okubo T, Hoyano M, Ozaki K, Inomata T.
    Circ J; 2024 Oct 25; 88(11):1770-1777. PubMed ID: 38897974
    [Abstract] [Full Text] [Related]

  • 14. Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial.
    Mora S, Caulfield MP, Wohlgemuth J, Chen Z, Superko HR, Rowland CM, Glynn RJ, Ridker PM, Krauss RM.
    Circulation; 2015 Dec 08; 132(23):2220-9. PubMed ID: 26408274
    [Abstract] [Full Text] [Related]

  • 15. Lipoprotein associated phospholipase A2 activity, apolipoprotein C3 loss-of-function variants and cardiovascular disease: The Atherosclerosis Risk In Communities Study.
    Pokharel Y, Sun W, Polfus LM, Folsom AR, Heiss G, Sharrett AR, Boerwinkle E, Ballantyne CM, Hoogeveen RC.
    Atherosclerosis; 2015 Aug 08; 241(2):641-8. PubMed ID: 26117401
    [Abstract] [Full Text] [Related]

  • 16. Increased apolipoprotein C3 drives cardiovascular risk in type 1 diabetes.
    Kanter JE, Shao B, Kramer F, Barnhart S, Shimizu-Albergine M, Vaisar T, Graham MJ, Crooke RM, Manuel CR, Haeusler RA, Mar D, Bomsztyk K, Hokanson JE, Kinney GL, Snell-Bergeon JK, Heinecke JW, Bornfeldt KE.
    J Clin Invest; 2019 Jul 11; 129(10):4165-4179. PubMed ID: 31295146
    [Abstract] [Full Text] [Related]

  • 17. Dyslipidemia and cardiovascular disease risk among the MASHAD study population.
    Hedayatnia M, Asadi Z, Zare-Feyzabadi R, Yaghooti-Khorasani M, Ghazizadeh H, Ghaffarian-Zirak R, Nosrati-Tirkani A, Mohammadi-Bajgiran M, Rohban M, Sadabadi F, Rahimi HR, Ghalandari M, Ghaffari MS, Yousefi A, Pouresmaeili E, Besharatlou MR, Moohebati M, Ferns GA, Esmaily H, Ghayour-Mobarhan M.
    Lipids Health Dis; 2020 Mar 16; 19(1):42. PubMed ID: 32178672
    [Abstract] [Full Text] [Related]

  • 18. Common variation in cholesteryl ester transfer protein: relationship of first major adverse cardiovascular events with the apolipoprotein B/apolipoprotein A-I ratio and the total cholesterol/high-density lipoprotein cholesterol ratio.
    Kappelle PJ, Gansevoort RT, Hillege HJ, Wolffenbuttel BH, Dullaart RP, PREVEND Study Group.
    J Clin Lipidol; 2013 Mar 16; 7(1):56-64. PubMed ID: 23351584
    [Abstract] [Full Text] [Related]

  • 19. Moderation of the effect of glycemia on the risk of cardiovascular disease in type 1 diabetes: The DCCT/EDIC study.
    Bebu I, Braffett BH, Orchard TJ, Lorenzi GM, Nathan DM, Herman WH, Lachin JM.
    Diabetes Res Clin Pract; 2021 Jan 16; 171():108591. PubMed ID: 33310124
    [Abstract] [Full Text] [Related]

  • 20. High density lipoprotein and its apolipoprotein-defined subspecies and risk of dementia.
    Koch M, DeKosky ST, Goodman M, Sun J, Furtado JD, Fitzpatrick AL, Mackey RH, Cai T, Lopez OL, Kuller LH, Mukamal KJ, Jensen MK.
    J Lipid Res; 2020 Mar 16; 61(3):445-454. PubMed ID: 31892526
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.